Literature DB >> 22821647

TOP2A amplification in breast cancer in the absence of that of HER-2: myth or reality?

Pierre-Jean Lamy, William Jacot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22821647      PMCID： PMC3528399          DOI： 10.1634/theoncologist.2011-0430

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  12 in total

1.  Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

Authors:  Michael F Press; Guido Sauter; Marc Buyse; Leslie Bernstein; Roberta Guzman; Angela Santiago; Ivonne E Villalobos; Wolfgang Eiermann; Tadeusz Pienkowski; Miguel Martin; Nicholas Robert; John Crown; Valerie Bee; Henry Taupin; Kerry J Flom; Isabelle Tabah-Fisch; Giovanni Pauletti; Mary-Ann Lindsay; Alessandro Riva; Dennis J Slamon
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

2.  HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.

Authors:  Angelo Di Leo; David Gancberg; Denis Larsimont; Minna Tanner; Tero Jarvinen; Ghizlane Rouas; Stella Dolci; Jean-Yves Leroy; Marianne Paesmans; Jorma Isola; Martine J Piccart
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

3.  EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.

Authors:  Rohit Bhargava; William L Gerald; Allan R Li; Qiulu Pan; Priti Lal; Marc Ladanyi; Beiyun Chen
Journal:  Mod Pathol       Date:  2005-08       Impact factor: 7.842

4.  ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.

Authors:  Jan C Brase; Marcus Schmidt; Thomas Fischbach; Holger Sültmann; Hans Bojar; Heinz Koelbl; Birte Hellwig; Jörg Rahnenführer; Jan G Hengstler; Mathias C Gehrmann
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

5.  The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.

Authors:  David G Hicks; Brian J Yoder; James Pettay; Eric Swain; Shannon Tarr; Marybeth Hartke; Marek Skacel; Joseph P Crowe; G Thomas Budd; Raymond R Tubbs
Journal:  Hum Pathol       Date:  2005-04       Impact factor: 3.466

6.  Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.

Authors:  T A Järvinen; M Tanner; M Bärlund; A Borg; J Isola
Journal:  Genes Chromosomes Cancer       Date:  1999-10       Impact factor: 5.006

Review 7.  Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.

Authors:  Atocha Romero; Miguel Martín; Maggie C U Cheang; José Antonio López García-Asenjo; Belén Oliva; Xiaping He; Miguel de la Hoya; Jose Ángel García Sáenz; Manuel Arroyo Fernández; Eduardo Díaz Rubio; Charles M Perou; Trinidad Caldés Llopis
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

8.  Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.

Authors:  Gottfried E Konecny; Giovanni Pauletti; Michael Untch; He-Jing Wang; Volker Möbus; Walther Kuhn; Christoph Thomssen; Nadia Harbeck; Ling Wang; Sophia Apple; Fritz Jänicke; Dennis J Slamon
Journal:  Breast Cancer Res Treat       Date:  2010-02-04       Impact factor: 4.872

9.  erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

Authors:  S Paik; J Bryant; C Park; B Fisher; E Tan-Chiu; D Hyams; E R Fisher; M E Lippman; D L Wickerham; N Wolmark
Journal:  J Natl Cancer Inst       Date:  1998-09-16       Impact factor: 13.506

10.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

Authors:  H B Muss; A D Thor; D A Berry; T Kute; E T Liu; F Koerner; C T Cirrincione; D R Budman; W C Wood; M Barcos
Journal:  N Engl J Med       Date:  1994-05-05       Impact factor: 91.245
View more
  1 in total

1.  Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas.

Authors:  Xiao-Ling Xu; Wei-Hui Zheng; Zhi-Xuan Fu; Zhu-Peng Li; Hua-Xia Xie; Xian-Xing Li; Lie-Hao Jiang; Yin Wang; Shuang-Mei Zhu; Wei-Min Mao
Journal:  Med Oncol       Date:  2014-11-29       Impact factor: 3.064
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.